Sana Biotechnology Inc (SANA) Stock Price, Quote & News

Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modifi...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 701 7914

Website: www.sana.com

Address:

188 East Blaine Street, Suite 400, Seattle, United States

BriOnH Aug. 7 at 5:12 PM

$SANA ER is coming up any day now, some report it as aug 10th, others 11th, etc, but ultimately it is when it is. Ideally this is THE main bullet I want to see in it: Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC451 and Expects to Dose First Patient in the Fourth Quarter of 2026 🙏🏻

1 · Reply

AlphaResearchHQ Aug. 7 at 4:18 PM

JUST UPDATED ITS STOCK PORTFOLIO 📊 (Part 4) More names from Google’s Q2 holdings update: 🏥 $OSCR — 481,988 shares 🧬 $BEAM — 321,604 shares 🧬 $VERA — 241,264 shares 🧬 $SANA — 2,812,500 shares This part of the portfolio highlights Google’s continued interest in healthcare, biotechnology, and next-generation medical innovation. Biotech can be a volatile space, but institutional positioning often gives us a look into areas where long-term capital is willing to take exposure. These companies may require patience, but the underlying themes are worth keeping on the radar. I’ll continue watching how these names develop and whether biotech starts attracting more attention from investors. Still watching from the sidelines? The next setup may not wait forever.

0 · Reply

EquityResearch6 Aug. 7 at 2:55 PM

GOOGLE $GOOGL JUST UPDATED ITS STOCK PORTFOLIO. Here are the major holdings as of the end of Q2: $OSCR — Oscar Health 481,988 shares $BEAM — Beam Therapeutics 321,604 shares $SANA — Sana Biotechnology 2,812,500 shares $FIG — Figma 215,582 shares Google’s portfolio shows exposure across several long-term innovation themes. Big technology companies often invest years ahead of mainstream adoption. Watching where companies like Google deploy capital can provide insight into the future technology landscape. Follow my profile for more AI, space, and next-generation technology trends. NFA. DYOR.

0 · Reply

LoveRetailFroth Aug. 7 at 1:17 PM

$RXRX $AMLX Good Morning August ☕️ My Bio 💎 s Over to you $SANA next on Monday! $TEM

0 · Reply

cta7978 Aug. 6 at 7:11 PM

$SANA So debating on taking a larger position again.. SANA has a pretty high valuation compared to IPSC.. IPSC has guided the will file their T1D IND by Q4 2026. It has a much smaller market cap, better cash runway, their own cell manufacturing (ready). Sana has been guiding to filing their IND "as soon as 2026". Is IPSC going to beat SANA to the punch? Outsourcing cell manufacturing going to hang SANA up until 2027 to file their IND? I like SANA's deal with Mayo clinic and they also have their Fusogen platform adding value. But is the UP421 trial artificially inflating SANA compared to IPSC? I might just take a position in both.. but haven't been following SANA closely. What's your take Brian?

3 · Reply

surrealskillerr Aug. 6 at 4:41 PM

$SANA Anyone here can help to understand news from $CELZ ? My knowledge goes only to the point that what they did is something to slow down and maybe even stop T1D onset. Which is mostly hype, because usually T1D is detected at rather late stage, when beta cells are mostly gone. Or I missed it completely? Would it complement any beta cell transplants approach?

1 · Reply

LoveRetailFroth Aug. 6 at 4:00 PM

$RXRX BEWARE Shorties😂🤑🚀 $ARBE $SANA $VIVO

0 · Reply

LoveRetailFroth Aug. 6 at 1:35 AM

$SANA Interesting day🍺

0 · Reply

BriOnH Aug. 6 at 1:04 AM

$SANA Harr on UP421 update. https://www.biopharminternational.com/view/crispr-islet-cells-cure-type-1-diabetes

3 · Reply

BBraggHillBoys Aug. 5 at 2:36 PM

$SANA hold $3.36 and reclaim $3.43, and that would be a meaningful confirmation.

1 · Reply

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

2026-07-13T13:30:18.000Z - 25 days ago

Sana Biotechnology announces publication of long-term diabetes data

Jul 13, 2026, 8:00 AM EDT - 25 days ago

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Jul 1, 2026, 9:00 AM EDT - 5 weeks ago

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

Jun 9, 2026, 4:00 PM EDT - 2 months ago

Sana Biotechnology Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 9:20 AM EDT - 2 months ago

Sana Biotechnology Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 4:05 PM EDT - 2 months ago

Sana Biotechnology to Present at June 2026 Investor Conferences

May 15, 2026, 9:00 AM EDT - 3 months ago

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

2026-05-12T22:28:22.000Z - 3 months ago

Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy

May 12, 2026, 5:20 PM EDT - 3 months ago

Sana Biotechnology Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 4:05 PM EDT - 3 months ago

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

2026-05-11T20:42:28.000Z - 3 months ago

Sana Biotechnology reports Q1 non-GAAP EPS (14c), consensus (15c)

May 11, 2026, 4:05 PM EDT - 3 months ago

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 4:00 PM EDT - 3 months ago

Sana Biotechnology Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Sana Biotechnology Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Sana Biotechnology Slides: Corporate presentation

2026-05-11T17:02:47.000Z - 3 months ago

Sana Biotechnology initiated with a Buy at Rodman & Renshaw

May 5, 2026, 4:05 PM EDT - 3 months ago

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Apr 27, 2026, 4:30 PM EDT - 3 months ago

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Sana Biotechnology Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Sana Biotechnology Proxy statement: Proxy filing

2026-04-14T13:23:10.000Z - 4 months ago

Sana Biotechnology price target raised to $7 from $6 at Wedbush

2026-04-13T20:18:08.000Z - 4 months ago

Sana Biotechnology announces SC451 strategic collaboration with Mayo Clinic

Apr 13, 2026, 7:00 AM EDT - 4 months ago

Sana Biotechnology Slides: Corporate presentation

2026-03-13T13:10:51.000Z - 5 months ago

Sana announces follow-up results from first-in-human study transplanting UP421

Mar 11, 2026, 1:40 PM EDT - 5 months ago

Sana Biotechnology Transcript: The Citizens Life Sciences Conference 2026

2026-03-03T22:25:38.000Z - 5 months ago

Sana Biotechnology files automatic mixed securities shelf

2026-03-03T21:25:24.000Z - 5 months ago

Sana Biotechnology reports Q4 EPS (16c), consensus (13c)

Mar 3, 2026, 4:05 PM EST - 5 months ago

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Mar 3, 2026, 3:00 PM EST - 5 months ago

Sana Biotechnology Annual report: Q4 2025

Mar 3, 2026, 3:00 PM EST - 5 months ago

Sana Biotechnology Earnings release: Q4 2025

Mar 2, 2026, 1:10 PM EST - 5 months ago

Sana Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 4:05 PM EST - 5 months ago

Sana Biotechnology to Present at March 2026 Investor Conferences

2026-02-17T14:16:15.000Z - 6 months ago

Sana Biotechnology appoints Piper as EVP, CFO

Jan 14, 2026, 12:45 PM EST - 7 months ago

Sana Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 7 months ago

Sana Biotechnology Slides: Corporate presentation

Jan 7, 2026, 4:26 PM EST - 7 months ago

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-06T15:25:24.000Z - 7 months ago

Sana Biotechnology price target raised to $7 from $6 at BofA

2025-12-08T14:05:59.000Z - 8 months ago

Sana Biotechnology announces publication of in vivo gene editing

Dec 8, 2025, 9:00 AM EST - 8 months ago

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Dec 3, 2025, 2:35 PM EST - 8 months ago

Sana Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:30 PM EST - 8 months ago

Sana Biotechnology Transcript: Citi Annual Global Healthcare Conference 2025

Nov 24, 2025, 4:05 PM EST - 9 months ago

Sana Biotechnology to Present at December 2025 Investor Conferences

Nov 12, 2025, 1:30 PM EST - 9 months ago

Sana Biotechnology Transcript: TD Cowen Immunology and Inflammation Summit

2025-11-06T23:25:54.000Z - 9 months ago

Sana Biotechnology reports Q3 EPS (16c), consensus (19c)

Nov 6, 2025, 7:00 AM EST - 9 months ago

Sana Biotechnology Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Sana Biotechnology Quarterly report: Q3 2025

Nov 5, 2025, 6:00 PM EST - 9 months ago

Sana Biotechnology Slides: Investor Presentation

2025-10-30T10:25:41.000Z - 10 months ago

Sana Biotechnology price target raised to $8 from $5 at Citizens JMP

2025-10-15T17:45:20.000Z - 10 months ago

Sana Biotechnology strength attributed to EMJ Capital long call

2025-09-24T11:45:09.000Z - 11 months ago

Wedbush bullish on Sana Biotechnology, initiates with an Outperform

2025-09-24T10:50:09.000Z - 11 months ago

Sana Biotechnology initiated with an Outperform at Wedbush

Sep 9, 2025, 9:30 AM EDT - 11 months ago

Sana Biotechnology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:30 AM EDT - 11 months ago

Sana Biotechnology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Sana Biotechnology Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 3:15 PM EDT - 1 year ago

Sana Biotechnology Transcript: Citi's Biopharma Back to School Conference

Aug 28, 2025, 8:00 AM EDT - 1 year ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX IQV MRNA

Aug 26, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology to Present at September 2025 Investor Conferences

Aug 20, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

2025-08-11T20:55:26.000Z - 1 year ago

Sana Biotechnology reports Q2 EPS (16c), consensus (21c)

Aug 11, 2025, 12:30 PM EDT - 1 year ago

Sana Biotechnology Quarterly report: Q2 2025

Aug 11, 2025, 12:30 PM EDT - 1 year ago

Sana Biotechnology Earnings release: Q2 2025

Aug 6, 2025, 11:24 PM EDT - 1 year ago

Sana Biotechnology Announces Pricing of Public Offering

Aug 6, 2025, 4:38 PM EDT - 1 year ago

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

MCRB

Aug 4, 2025, 11:35 AM EDT - 1 year ago

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Jun 23, 2025, 10:05 AM EDT - 1 year ago

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Jun 10, 2025, 8:40 AM EDT - 1 year ago

Sana Biotechnology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

Jun 4, 2025, 2:35 PM EDT - 1 year ago

Sana Biotechnology Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Sana Biotechnology Slides: Corporate Presentation

May 28, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology to Present at June 2025 Investor Conferences

May 13, 2025, 12:20 PM EDT - 1 year ago

Sana Biotechnology Transcript: BofA Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

May 8, 2025, 4:00 PM EDT - 1 year ago

Sana Biotechnology Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Sana Biotechnology Quarterly report: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Sana Biotechnology Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Sana Biotechnology Proxy statement: Proxy Filing

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Sana Biotechnology Annual report: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Sana Biotechnology Earnings release: Q4 2024

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

BriOnH Aug. 7 at 5:12 PM

1 · Reply

AlphaResearchHQ Aug. 7 at 4:18 PM

0 · Reply

EquityResearch6 Aug. 7 at 2:55 PM

0 · Reply

LoveRetailFroth Aug. 7 at 1:17 PM

$RXRX $AMLX Good Morning August ☕️ My Bio 💎 s Over to you $SANA next on Monday! $TEM

0 · Reply

cta7978 Aug. 6 at 7:11 PM

3 · Reply

surrealskillerr Aug. 6 at 4:41 PM

1 · Reply

LoveRetailFroth Aug. 6 at 4:00 PM

$RXRX BEWARE Shorties😂🤑🚀 $ARBE $SANA $VIVO

0 · Reply

LoveRetailFroth Aug. 6 at 1:35 AM

$SANA Interesting day🍺

0 · Reply

BriOnH Aug. 6 at 1:04 AM

$SANA Harr on UP421 update. https://www.biopharminternational.com/view/crispr-islet-cells-cure-type-1-diabetes

3 · Reply

BBraggHillBoys Aug. 5 at 2:36 PM

$SANA hold $3.36 and reclaim $3.43, and that would be a meaningful confirmation.

1 · Reply

LoveRetailFroth Aug. 5 at 1:48 PM

$RXRX Interesting, I am a hypoglycemia & Diabetes (ic) investor😂🤣☕️ $AMLX $SANA

0 · Reply

Inflames_swe Aug. 4 at 7:44 PM

$SANA not that volume and we going up. Sure i like it anyone know why?

0 · Reply

Poshfox Aug. 4 at 6:00 PM

$SANA does anyone have a link to mm abbreviations? Who is mm/mf? Never seen them before.

0 · Reply

LoveRetailFroth Aug. 4 at 1:53 PM

$SANA Good Morning ☕️🚀🚀🚀😂

0 · Reply

bubbaxyz Aug. 3 at 9:55 PM

$SANA another jackson pos

0 · Reply

LoveRetailFroth Aug. 3 at 1:53 PM

$AMLX Good Morning August ☕️ My Bio 💎 s $RXRX $SANA $TEM

0 · Reply

mastergambler Aug. 1 at 12:10 PM

$SANA unless the ongoing war gets uglier and it seems to be heading that way. Also, these biotech companies even if legit, use a lot of money to fund their experiments or fraudulent activity, whereby diluting investors equity. https://youtu.be/2gvboQnLJNM?si=vTg-hAbIVquCJSRO

2 · Reply

BBraggHillBoys Aug. 1 at 1:32 AM

$SANA sellers tried to push it below $3, but did not succeed; we'll catch that bull confirmation next week.

0 · Reply

mastergambler Jul. 31 at 6:35 PM

$SANA

0 · Reply

LoveRetailFroth Jul. 31 at 1:48 PM

$RXRX Good Morning ☕️ SITUATIONAL AWARENESS fucking Shorties😂 $VIVO $SANA $ARBE

0 · Reply

LoveRetailFroth Jul. 30 at 10:08 PM

$TEM Buy & HOLD this, $RXRX $SANA $AMLX 🍺

0 · Reply

LoveRetailFroth Jul. 30 at 1:21 PM

$AMLX Good Morning ☕️ My Bio 💎 s $SANA $RXRX $TEM

0 · Reply

Market Cap	976.81M
Revenue (ttm)	0.00
Net Income (ttm)	-244.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	889,014
Avg Vol	3,381,934
Day's Range	N/A - N/A
Shares Out	278.29M
Stochastic %K	64%
Beta	2.16
Analysts	Strong Sell
Price Target	$9.50